At month 6, the least-squares mean change in A1c levels from baseline was −1.4% (95% CI, −1.5 to −1.3). By month 12, both fasting and postprandial glucose levels decreased following treatment with ...
The approval in adolescent patients was based on evidence from the phase 3 SINUS-24 and SINUS-52 trials. The Food and Drug Administration (FDA) has expanded the approval of Dupixent ® (dupilumab) to ...
A regulatory decision for expansion of the CRSwNP indication to adolescents is expected on September 15, 2024. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental ...
TORONTO, Oct. 22, 2025 /CNW/ - Health Canada has approved Dupixent® (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) ...
Objective: We sought to evaluate the efficacy and safety of vildagliptin, a new dipeptidyl peptidase-4 inhibitor, added to metformin during 24 weeks of treatment in patients with type 2 diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback